| [1] |
FUNG J, SETO WK, LAI CL, et al. Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy[J]. J Hepatol, 2011, 54(2): 195-200. DOI: 10.1016/j.jhep.2010.06.031. |
| [2] |
LEE HA, LEE HW, KIM IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase[J]. Aliment Pharmacol Ther, 2020, 52(1): 196-204. DOI: 10.1111/apt.15741. |
| [3] |
CHAO DT, LIM JK, AYOUB WS, et al. Systematic review with meta-analysis: The proportion of chronic hepatitis B patients with normal alanine transaminase≤40 IU/L and significant hepatic fibrosis[J]. Aliment Pharmacol Ther, 2014, 39(4): 349-358. DOI: 10.1111/apt.12590. |
| [4] |
KENNEDY P, SANDALOVA E, JO J, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B[J]. Gastroenterology, 2012, 143(3): 637-645. DOI: 10.1053/j.gastro.2012.06.009. |
| [5] |
KENNEDY P, SANDALOVA E, JO J, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B[J]. Gastroenterology, 2012, 143(3): 637-645. DOI: 10.1053/j.gastro.2012.06.009. |
| [6] |
PÉNEAU C, IMBEAUD S, LA BELLA T, et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma[J]. Gut, 2021. DOI: 10.1136/gutjnl-2020-323153.[Online ahead of print] |
| [7] |
YIP TC, WONG GL, WONG VW. Negligible risk of HCC in chronic hepatitis B patients in immune-tolerant phase: Myth or fact[J]. Clin Mol Hepatol, 2021. DOI: 10.3350/cmh.2021.0019.[Online ahead of print] |
| [8] |
KIM HL, KIM GA, PARK JA, et al. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B[J]. Gut, 2020. DOI: 10.1136/gutjnl-2020-321309.[Online ahead of print] |
| [9] |
JENG WJ, LOK AS. Should treatment indications for chronic hepatitis B be expanded?[J]. Clin Gastroenterol Hepatol, 2020. DOI: 10.1016/j.cgh.2020.04.091.[Online ahead of print] |
| [10] |
LI J, ZOU B, YEO YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398. DOI: 10.1016/S2468-1253(19)30039-1. |
| [11] |
TOUT I, LOUREIRO D, MANSOURI A, et al. Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development[J]. J Hepatol, 2020, 73(2): 409-422. DOI: 10.1016/j.jhep.2020.04.013. |
| [12] |
HSU YC, HUANG YT. Editorial: Risk assessment for chronic hepatitis B patients in the immune tolerant phase-both definition and selection matter[J]. Aliment Pharmacol Ther, 2020, 52(1): 213-214. DOI: 10.1111/apt.15798. |
| [13] |
SHARIF A, ABBAS Z, AHMED S, et al. Effect of non-alcoholic fatty liver disease on transaminase levels and transient elastography in patients with chronic hepatitis B[J]. Cureus, 2019, 11(10): e5995. DOI: 10.7759/cureus.5995. |
| [14] |
SONNEVELD MJ, BROUWER WP, HANSEN BE, et al. Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis[J]. Aliment Pharmacol Ther, 2020, 52(8): 1399-1406. DOI: 10.1111/apt.16067. |
| [15] |
van CAMPENHOUT M, van BÖMMEL F, PFEFFERKORN M, et al. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment[J]. Hepatology, 2018, 68(3): 839-847. DOI: 10.1002/hep.29872. |
| [16] |
SCHOEMAN JC, HOU J, HARMS AC, et al. Metabolic characterization of the natural progression of chronic hepatitis B[J]. Genome Med, 2016, 8(1): 64. DOI: 10.1186/s13073-016-0318-8. |
| [17] |
MCMAHON BJ. The natural history of chronic hepatitis B virus infection[J]. Hepatology, 2009, 49(5 Suppl): s45-s55. DOI: 10.1002/hep.22898. |
| [18] |
TEBANI A, GUMMESSON A, ZHONG W, et al. Integration of molecular profiles in a longitudinal wellness profiling cohort[J]. Nat Commun, 2020, 11(1): 4487. DOI: 10.1038/s41467-020-18148-7. |
DownLoad: